- * Completion of treatment period in study CSL312\_3003 (NCT05819775)
- * The participant responded to CSL312 treatment with no or very limited number of HAE attacks during the CSL312\_3003 study
- * The participant experienced no clinically significant adverse effects associated with CSL312 treatment
- * In the opinion of the treating physician, the participant continues to receive benefit from CSL312
- * There is no other suitable alternative prophylactic treatment available at the time of consenting into the Post Study Access program
Hereditary Angioedema (HAE)
Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study
NCT07159464 | EXPANDED_ACCESS
This protocol for post study access allows pediatric participants (2-11 years old at the time of consent) with HAE who have completed study CSL312\_3003 (NCT05819775) to continue treatment with CSL312 for routine prevention of HAE attacks. The continuing treatment with the study product will be administered under a Post Study Access program in accordance with the applicable laws and regulations, to be dictated by CSL Behring (Sponsor) and approved by the appropriate local/central Ethics Committees and all other competent authorities required by law, as applicable.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov